What is the recommended treatment for immune thrombocytopenia (ITP)?

Treatment for Immune Thrombocytopenia (ITP)

For newly diagnosed adult ITP requiring treatment (platelet count <30 × 10⁹/L), initiate longer courses of corticosteroids as first-line therapy, with prednisone (0.5-2.0 mg/kg/day) or dexamethasone (40 mg/day for 4 days) being equally acceptable options. 1

Initial Diagnostic Workup

Before initiating treatment, the American Society of Hematology recommends:

• Test all patients for HCV and HIV to identify secondary causes 1
• Screen for H. pylori infection (via urea breath test, stool antigen, or endoscopic biopsy) and provide eradication therapy if positive 1
• Bone marrow examination is NOT necessary in patients presenting with typical ITP, regardless of age 1
• Further investigation is only warranted if abnormalities exist beyond isolated thrombocytopenia (excluding iron deficiency findings) 1

First-Line Treatment Algorithm

When to Treat

• Treat adults with platelet counts <30 × 10⁹/L 1
• Observation is appropriate for asymptomatic patients with higher counts 1

Primary First-Line Options

Corticosteroids (preferred):

• Longer courses of corticosteroids are preferred over shorter courses or IVIg alone 1
• Either prednisone or dexamethasone is acceptable; recent data shows no clear superiority 1
• Add IVIg (1 g/kg as single dose) to corticosteroids when rapid platelet increase is required (e.g., active bleeding, urgent procedures) 1

Alternative First-Line (if corticosteroids contraindicated):

• Use either IVIg or anti-D immunoglobulin (in appropriate Rh-positive, non-splenectomized patients) 1

Important caveat: The 2019 ASH guidelines recommend against combining rituximab with corticosteroids as initial therapy, as this combination has not demonstrated sufficient benefit to justify the added toxicity and cost 1

Second-Line Treatment: A Decision Algorithm

For patients who fail initial corticosteroid therapy, treatment selection depends critically on disease duration and patient priorities 1:

For ITP Duration <12 Months

Primary recommendation: Thrombopoietin receptor agonists (TPO-RAs) over rituximab 1

• TPO-RAs (romiplostim or eltrombopag) provide greater durability of response with ongoing use 1
• Delay splenectomy when possible during the first 12 months due to potential for spontaneous remission 1
• Rituximab remains an option for patients who cannot afford TPO-RAs or strongly prefer avoiding long-term medication 1

For ITP Duration >12 Months

The choice depends on patient values:

For patients prioritizing avoidance of long-term medication:

• Rituximab is preferred over splenectomy despite lower durable response rates, due to operative risks and irreversible consequences of asplenia (infection risk, thrombosis risk) 1
• Splenectomy remains appropriate for patients with significant bleeding, lack of response to other therapies, or quality of life considerations 1

For patients prioritizing avoidance of surgery:

• TPO-RAs are preferred over rituximab due to greater durability of response 1
• Both romiplostim (weekly subcutaneous injection) and eltrombopag (daily oral) are effective; choice depends on patient preference regarding administration route 1

For patients prioritizing durable response:

• Either splenectomy or TPO-RAs are acceptable, with the decision based on willingness to undergo surgery versus long-term medication 1

Specific Second-Line Recommendations

The American Society of Hematology strongly recommends:

• Splenectomy for patients who have failed corticosteroid therapy (Grade 1B) 1
• TPO-RAs for patients at bleeding risk who relapse after splenectomy or have contraindications to splenectomy and have failed at least one other therapy (Grade 1B) 1
• Laparoscopic and open splenectomy offer similar efficacy; choose based on surgical expertise and patient factors 1

Conditional recommendations:

• Rituximab may be considered for bleeding-risk patients who failed one therapy line 1
• TPO-RAs may be considered earlier (after failing corticosteroids/IVIg) in bleeding-risk patients who have not had splenectomy 1
• Fostamatinib (spleen tyrosine kinase inhibitor) is an additional option for refractory cases 2

Special Populations

Pregnancy

• Treat pregnant patients requiring intervention with either corticosteroids or IVIg 1
• Treatment is not indicated unless platelets <20,000/μL or clinically significant bleeding occurs in first 8 months 3
• Target platelet count >70,000/μL for epidural anesthesia and delivery 3
• Start prednisone 20-60 mg daily at 34-36 weeks gestation; add IVIG 1-2 g/kg if insufficient response 3
• Mode of delivery should be based on obstetric indications, not platelet count alone 1

Children and Adolescents

• Splenectomy is recommended for chronic/persistent ITP with significant bleeding unresponsive to corticosteroids, IVIg, and anti-D 1
• Delay splenectomy for at least 12 months unless severe disease unresponsive to other measures 1
• High-dose dexamethasone may be considered for ongoing bleeding despite standard therapies or as splenectomy alternative 1

Secondary ITP

HIV-associated ITP:

• Treat the underlying HIV infection with antiretroviral therapy first unless clinically significant bleeding complications exist (Grade 1A) 1
• If ITP treatment required: use corticosteroids, IVIg, or anti-D initially 1

HCV-associated ITP:

• Consider antiviral therapy in absence of contraindications, but monitor platelets closely (interferon may worsen thrombocytopenia) 1
• If ITP treatment required: IVIg is the preferred initial treatment 1

H. pylori-associated ITP:

• Administer eradication therapy to all patients with confirmed H. pylori infection (Grade 1B) 1

Post-Splenectomy Management

• Do NOT treat asymptomatic patients after splenectomy with platelet counts >30 × 10⁹/L 1
• For post-splenectomy relapse: TPO-RAs are strongly recommended 1

Emerging Therapies

While not yet incorporated into standard guidelines, several novel agents show promise for refractory ITP 4:

• Neonatal Fc receptor inhibitors (currently under investigation) 5, 4
• Bruton's tyrosine kinase inhibitors 6, 5, 4
• Daratumumab (CD38 antibody) showed 48% response rate in heavily pretreated patients in phase II trial 7
• Complement inhibitors for specific refractory cases 5, 4

Critical Pitfalls to Avoid

• Do not routinely combine rituximab with corticosteroids upfront—insufficient evidence of benefit 1
• Do not rush to splenectomy in the first year—spontaneous remission remains possible 1
• Do not perform bone marrow biopsy routinely—diagnosis is clinical 1
• Do not continue treatment in asymptomatic post-splenectomy patients with platelets >30 × 10⁹/L 1
• Reassess treatment decisions regularly, as patient preferences and disease characteristics evolve over time 1